Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6HDO3)

Drug Name
INOGATRAN Drug Info
Synonyms
Inogatran; Inogatran [INN]; UNII-428409I84L; CHEMBL114715; 155415-08-0; INOGATRAN (ASTRA-ZENECA); {[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID; 428409I84L; N-((1R)-2-Cyclohexyl-1-(((2S)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine; 2-[[(2R)-3-cyclohexyl-1-[(2S)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid; IGN; AC1Q5JWR; AC1L24ET; SCHEMBL22745; SCHEMBL22747
Indication
Disease Entry ICD 11 Status REF
Myocardial infarction BA41-BA43 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
66005
CAS Number
CAS 155415-08-0
TTD Drug ID
DM6HDO3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Coagulation factor IIa (F2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Argatroban DMFI46A Thrombosis DB61-GB90 Approved [3]
Pyridoxal Phosphate DMO2K0J Malnutrition 5B50-5B71 Approved [4]
Bivalirudin DMECRX1 Thrombocytopenia 3B64 Approved [5]
Ximelegatran DMU8ANS Myocardial infarction BA41-BA43 Approved [6]
Dabigatran DMDI6R4 Stroke 8B20 Approved [7]
Desirudin Recombinant DM2BTFN Coagulation defect 3B10.0 Approved [8]
Human prothrombin complex concentrate DMPHVQ1 Bleeding disorder GA20-GA21 Approved [9]
Lepirudin DM1I3D5 Thrombocytopenia 3B64 Approved [10]
Anisindione DM2C48U Coagulation defect 3B10.0 Approved [11]
ATryn antithrombin DM79Y2T Multiple sclerosis 8A40 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005012)
2 Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther. 1996 Jun;277(3):1276-83.
3 Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
4 New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
5 New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
6 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
7 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
10 Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
11 Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
12 Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.